Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs

Dr. Myers to support Sera's commitment to reduce healthcare disparities among underserved communities

Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Woodrow Myers, M.D., M.B.A., joins Sera as an advisor focusing on public and political affairs.

Dr. Myers will work on a multi-disciplinary effort to execute a national and state-specific political and public affairs strategy focused on Health Equity and Disparities related to pregnancy and parturition, further emphasizing the Company’s efforts to help address the healthcare disparities that disproportionately affect underserved communities.

“We are honored to have Dr. Myers join the Sera Prognostics team, bringing his extensive experience and leadership in addressing health equity and disparities,” said Gregory C. Critchfield, M.D., M.S., Chairman, and CEO of Sera Prognostics. “Dr. Myers has coupled his passion for the highest standards of patient care and management with leadership roles in several of our largest and most innovative healthcare enterprises.”

Dr. Myers is a nationally recognized leader in developing medical quality initiatives and advanced healthcare management programs. He serves as National Health Policy Advisor for the Wellness and Equity Alliance. Dr. Myers is on the boards of Personalis, Inc., Freespira Inc., and the Public Health Policy Committee of eHealth Inc. He has also served as Chief Medical Officer and Chief Healthcare Strategist for Blue Cross Blue Shield of Arizona, Chief Executive Officer for Valitàs Health Services (Corizon Health), and consultant to the California Endowment. In addition, Dr. Myers has served on multiple public, private, and nonprofit boards, including Express Scripts, Genomic Health, LipoScience, and SynGen. In higher education, he served on the Board of Trustees of Stanford University, the Board of Overseers of Harvard University, and the Board of Trustees of the Charles R. Drew University of Medicine and Science.

“I am excited to work with the team at Sera Prognostics who share my commitment to improving the quality, availability, and efficiency of healthcare around the globe,” said Dr. Myers. “I am looking forward to utilizing my passion for innovation and technology upgrades that will improve healthcare delivery and human longevity.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.